A federal appellate court has upheld the Drug Enforcement Administration’s denial of a Seattle doctor’s request to use psilocybin, the active ingredient in magic mushrooms, to treat terminally ill cancer patients.
Dr. Sunil Aggarwal, co-director of the Advanced Integrative Medical Science Institute, had sought approval from the DEA to provide psilocybin to his patients with late-stage and terminal cancer in accordance with federal and state right-to-try laws.
Since 2021, he’s sought access to the hallucinogen, a Schedule 1 controlled substance, to treat his patients for anxiety and depression but he’s been unable to find a supplier willing to provide him with psilocybin, according to the opinion.
Read more
